187 related articles for article (PubMed ID: 35298544)
1. Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia.
Shelton DN; Bhagavatula P; Sepulveda N; Beppu L; Gandhi S; Qin D; Hauenstein S; Radich J
PLoS One; 2022; 17(3):e0265278. PubMed ID: 35298544
[TBL] [Abstract][Full Text] [Related]
2. Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay.
Chung HJ; Hur M; Yoon S; Hwang K; Lim HS; Kim H; Moon HW; Yun YM
Ann Lab Med; 2020 Jan; 40(1):72-75. PubMed ID: 31432643
[TBL] [Abstract][Full Text] [Related]
3. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
Brown JT; Beldorth IJ; Laosinchai-Wolf W; Fahey ME; Jefferson KL; Ruskin AK; Roth JJ; Cai L; Watt CD; Press RD; Yang F; Hedges JB; Andruss BF
J Mol Diagn; 2019 Jul; 21(4):718-733. PubMed ID: 31026597
[TBL] [Abstract][Full Text] [Related]
4. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.
Martinez RJ; Kang Q; Nennig D; Bailey NG; Brown NA; Betz BL; Tewari M; Thyagarajan B; Bachanova V; Mroz P
Arch Pathol Lab Med; 2022 Jan; 146(1):92-100. PubMed ID: 33769465
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
[TBL] [Abstract][Full Text] [Related]
7. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
[TBL] [Abstract][Full Text] [Related]
8. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.
Furuya D; Moriai M; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
Int J Clin Oncol; 2019 Jul; 24(7):871-875. PubMed ID: 30798394
[TBL] [Abstract][Full Text] [Related]
9. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
[TBL] [Abstract][Full Text] [Related]
10. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
11. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
[TBL] [Abstract][Full Text] [Related]
12. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
14. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.
Cortés AA; Olmedillas S; Serrano-López J; Lainez-González D; Castaño T; Iñiguez R; Lopez-Lorenzo JL; García A; Atance M; Sánchez RNS; Lopez CB; Arranz MG; Sillero PL; Alonso-Dominguez JM
Mol Diagn Ther; 2020 Oct; 24(5):593-600. PubMed ID: 32875515
[TBL] [Abstract][Full Text] [Related]
16. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
Moore FR; Rempfer CB; Press RD
Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
[TBL] [Abstract][Full Text] [Related]
17. Molecular
Marin AM; Wosniaki DK; Sanchuki HBS; Munhoz EC; Nardin JM; Soares GS; Espinace DC; de Holanda Farias JS; Veroneze B; Becker LF; Costa GL; Beltrame OC; de Oliveira JC; Cambri G; Zanette DL; Aoki MN
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373266
[TBL] [Abstract][Full Text] [Related]
18. Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR.
Lund HL; Hughesman CB; McNeil K; Clemens S; Hocken K; Pettersson R; Karsan A; Foster LJ; Haynes C
Anal Bioanal Chem; 2016 Feb; 408(4):1079-94. PubMed ID: 26631023
[TBL] [Abstract][Full Text] [Related]
19. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
[TBL] [Abstract][Full Text] [Related]
20. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
[Next] [New Search]